Treatment of non-alcoholic steatohepatitis with recombinant Orosomucoid 2, an acute phase protein that attenuates the Erk1/2-PPARγ-Cd36 signaling pathway
Li Li, Haoming Sun, Jionghao Chen, Cong Ding, Xiaojun Yang, Hua Han, Qingzhu Sun
This study shows that recombinant Orm2 treatment reduces hepatic steatosis, inflammation, and fibrosis in NASH models by inhibiting the Erk1/2-PPARγ-Cd36 pathway.
bioRxiv · Oct 22, 2022 · PreprintMolecular Biology